Navigation Links
VIA Pharmaceuticals Names Rebecca Taub Senior Vice President of Research and Development
Date:1/16/2008

dent of research in metabolic diseases since 2004. While at Roche she oversaw drug discovery programs in diabetes, dyslipidemia and obesity, including target identification, lead optimization and advancement of preclinical candidates into clinical development. From 2000 through 2003, Dr. Taub worked at Bristol-Myers Squibb Co. and DuPont Pharmaceutical Company, which was acquired by Bristol-Myers in 2001, in a variety of positions, including executive director of neuroscience biology and executive director of CNS and obesity research.

"VIA's strategy of addressing significant unmet medical needs of patients with cardiovascular disease by targeting the root cause of vascular inflammation is innovative and has significant potential," said Dr. Taub. "I look forward to supporting the excellent clinical and development work that is taking place and ensuring additional clinical candidates are brought forward."

Before becoming a pharmaceutical executive, Dr. Taub served in a number of academic medicine and clinical research positions. She was a tenured professor of genetics and medicine at the University of Pennsylvania School of Medicine from 1997 to 2001, and she remains an adjunct professor. Earlier she was an assistant professor at the Joslin Diabetes Center of Harvard Medical School, Harvard University and an associate investigator with the Howard Hughes Medical Institute. She is the author of more than 120 research articles. Dr. Taub received her M.D. from Yale University School of Medicine and B.A. from Yale College.

About VIA Pharmaceuticals, Inc.

VIA Pharmaceuticals, Inc. is a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease. VIA is building a pipeline of small-molecule drugs that target a significant unmet medical need: reducing inflammation in the blood vessel wall, which is an underlying cause of atherosclerosis and its complications, including heart attack and stroke. The comp
'/>"/>

SOURCE VIA Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference
2. Cerimon Pharmaceuticals Names Matthew J. Meyer its General Counsel and Vice President of Business Development and Licensing
3. QuatRx Pharmaceuticals to Present at 26th Annual JP Morgan Healthcare Conference
4. Rib-X Pharmaceuticals Initiates Two Phase 2 Studies for Novel Antibiotic Compound RX-1741
5. Intercept Pharmaceuticals Names Dr. Luciano Adorini Chief Scientific Officer
6. Onyx Pharmaceuticals to Present at JPMorgan Healthcare Conference
7. Strativa Pharmaceuticals, the Proprietary Products Division of Par Pharmaceutical, Provides an Update on Development Status of Pafuramidine and Other in-Licensed Products
8. Access Pharmaceuticals Appoints Jeffrey B. Davis as CEO
9. Wyeth Will Pursue Claim for Damages Resulting From Teva Pharmaceuticals Launch of Generic Pantoprazole in Violation of PROTONIX Patent
10. Co-Inventor of Amgens Aranesp(R) Technology Directs Worldwide Patent Strategy for Diffusion Pharmaceuticals First-in-Class Oxygen Enhancing Therapeutics
11. Memory Pharmaceuticals Initiates Phase 2a Trial of MEM 3454 in Cognitive Impairment Associated with Schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... PA and London (PRWEB) November 21, 2014 ... December will explore what comes next for ALS research and ... sites. , After the Ice Bucket Challenge: Where Does ... Cudkowicz, Date: Tuesday, 2 December 2014, Time: 1:30pm ... , Join expert speaker Dr. Merit Cudkowicz, Julianne Dorn ...
(Date:11/22/2014)... Prominent academics, leaders of the biopharmaceutical ... 3rd at Genetic Rx, a networking conference of ... place at the Joseph B. Martin Conference Center ... present and future of genetic medicines—including siRNA, ASOs, ... well as the treatment of patients with rare ...
(Date:11/22/2014)... 21, 2014 RURO, Inc., a ... has released Limfinity® version 5.1.4. , RURO’s deployment ... Limfinity® than ever in RURO’s 8 year history. ... framework enhancement. Limfinity® version 5.1.4 is the perfect ... beyond bug fixes! , Limfinity® 5.1.4 release highlights ...
(Date:11/22/2014)... (PRWEB) November 22, 2014 The ... Analytical, Preparative), by Material (Metal, Glass, Plastic), by ... TLC, SFC] - Forecast to 2018” analyses and ... challenges in North America, Europe, Asia, and Rest ... tables and 15 figures spread through 135 pages ...
Breaking Biology Technology:DrugDev Webinars in December to Explore What Comes Next for ALS Research and How We Can Make Life Easier for Clinical Sites 2Pioneering Academics and Key Industry Leaders to Discuss Rare Diseases and the Emergence of New Genetic Medicines at Genetic Rx on December 3rd 2RURO Announces Limfinity® version 5.1.4 2Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 2Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 3Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 4Chiral Chromatography Columns Market worth $87.8 Million by 2018 - New Research Report by MarketsandMarkets 5
... Signature pitchman, Billy Mays ENDORSES AND USES What Odor?® , ... Phoenix, ... to announce the launch of a massive marketing campaign for their flagship ... ,Nelson Grist, Founder and CEO of For The Earth Corp, anxiously awaits ...
... - BioMS Medical Corp (TSX: MS), a leading developer ... effective on March 16, 2009 the exercise term of ... holder to purchase one Class A common share at ... from March 23, 2009 to December 31, 2009. , ...
... invivodata, inc., ( http://www.invivodata.com ) the industry ... solutions and services for global clinical research, ... at upcoming international events to be delivered ... and regulatory consulting division, PRO Consulting(R) ( ...
Cached Biology Technology:Billy Mays Endorses New Odor Eliminating Product, What Odor? 2BioMS Medical warrant extension 2invivodata and PRO Consulting to Present at International Industry Events 2invivodata and PRO Consulting to Present at International Industry Events 3
(Date:11/6/2014)... occur because of metastasis, yet progress in preventing ... , "It,s been particularly challenging to design drugs ... fellow in systems biology at Harvard Medical School. ... after they,ve already metastasized." , Gujral and colleagues ... help researchers better understand how metastasis begins. Their ...
(Date:11/5/2014)... career to understanding the Earth,s climate and communicating ... deputy director and regional climatologist for the Western ... Redmond has more than three decades of experience ... data to the general public. , At its ... December 15-19, 2014 the American Geophysical Union (AGU) ...
(Date:11/4/2014)... PA) – Temple University School of Medicine announced ... winner, an initiative funded by the Bill & ... Professor of Obstetrics, Gynecology and Reproductive Sciences; and ... Temple University School of Medicine will pursue an ... "Maternal Blood Biomarkers to Assess Fetal Neurodevelopment.", Grand ...
Breaking Biology News(10 mins):Migration negation 2Migration negation 3Nevada climatologist to be honored at AGU Fall Meeting for lifetime of public outreach 2Temple University School of Medicine receives Grand Challenges Explorations grant 2
... Université Laval biologist Connie Lovejoy has discovered new ... findings are reported in the January 12 edition ... discovered a new group of microscopic organisms, which ... extremely small size, measured in millionths of a ...
... to protect against human papillomavirus, has moved from scientific ... to make progress. While HPV vaccine efforts had the ... researchers are developing vaccines for cancers that are not ... system into attacking cancerous cells. Today at the ...
... from West Africa were cracking nuts with stone tools ... The result suggests chimpanzees developed this behaviour on their ... trait inherited from our common ancestor. Julio Mercader, Christophe ... site in Cote d'Ivoire, the only known prehistoric chimpanzee ...
Cached Biology News:Cancer vaccines -- Taking a jab at cancer by stimulating the immune system 2Cancer vaccines -- Taking a jab at cancer by stimulating the immune system 3Cancer vaccines -- Taking a jab at cancer by stimulating the immune system 4Cancer vaccines -- Taking a jab at cancer by stimulating the immune system 5The chimpanzee stone age 2
Human CCL26/Eotaxin-3 MAb (Clone 115002)...
Normal sheep serum collected from healthy normal sheep...
Agarose-ME, 500 g. Suitable for immunoelectrophoresis.Gel point (1.5%): 36 1.5 C, EEO (-mr): 0.16-0.19, Gel strength (1%): > 1000 g/cm2. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Bio...
Pooled normal sreum with 0.1% sodium azide as preservative...
Biology Products: